Higuchi Yuki, Soga Tomoko, Parhar Ishwar S
Brain Research Institute, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia.
Front Mol Neurosci. 2018 Sep 14;11:339. doi: 10.3389/fnmol.2018.00339. eCollection 2018.
Monoamine oxidase A (MAO-A) is an enzyme that regulates the levels of monoamine neurotransmitters, such as serotonin, noradrenaline and dopamine and it has been used as a therapeutic target for depression. However, MAO-A inhibitors, which directly acts on MAO-A protein, have limited use due to their adverse effects. microRNAs (miRNAs) are 18-22 nucleotide long, small non-coding RNAs, which have recently emerged as regulators of protein levels that could potentially be new therapeutic targets for psychiatric disorders. This review article aims to discuss the current status of the treatment for depression with MAO-A inhibitors and the regulatory factors of MAO-A. Further, the review also proposes possible regulatory mechanisms of MAO-A by miRNAs, which leads to better understanding of the pathology of depressive disorders and their potential use as therapeutic agents.
单胺氧化酶A(MAO-A)是一种调节单胺类神经递质水平的酶,如血清素、去甲肾上腺素和多巴胺,它已被用作抑郁症的治疗靶点。然而,直接作用于MAO-A蛋白的MAO-A抑制剂由于其副作用而使用受限。微小RNA(miRNA)是长度为18 - 22个核苷酸的小型非编码RNA,最近已成为蛋白质水平的调节因子,可能成为精神疾病的新治疗靶点。这篇综述文章旨在讨论MAO-A抑制剂治疗抑郁症的现状以及MAO-A的调节因子。此外,该综述还提出了miRNA对MAO-A可能的调节机制,这有助于更好地理解抑郁症的病理及其作为治疗药物的潜在用途。